Understand the source comparison
VIP Mold Illness: Treatment Comparison
Understanding treatment approaches requires distinguishing between environmental control, symptomatic management, and mechanism-targeted interventions. The following comparison outlines the primary strategies used in clinical practice. Environmental remediatio
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding treatment approaches requires distinguishing between environmental control, symptomatic management, and mechanism-targeted interventions. The following comparison outlines the primary strategies used in clinical practice.
- Environmental remediation + avoidance
- Eliminates ongoing biotoxin exposure; necessary but insufficient alone
- Permanent environmental change
- 15–20% symptom resolution as monotherapy
- Essential first step. VIP therapy fails without removal of exposure source. Genetic susceptibility means stricter thresholds than standard mold remediation
- Cholestyramine or bile acid sequestrant binders
- Binds circulating biotoxins in enterohepatic circulation for fecal excretion
- 2–6 months at 2–4 doses daily
- 40–50% symptom improvement
- Proven biotoxin clearance mechanism supported by published pharmacokinetic data. Side effects (constipation, nutrient depletion) require management
- Intranasal VIP replacement therapy
- Restores vasoactive intestinal peptide levels; shifts immune cells to anti-inflammatory phenotype; increases regulatory T-cell function
- 3–9 months at 50 mcg 4× daily
- 75–80% improvement in patients who complete prerequisite steps
- Most targeted intervention for neuropeptide deficiency. Requires MARCoNS eradication and biotoxin clearance first. Clinical observations exceed controlled trial data
- Antifungal medications (systemic or nasal)
- Eradicates MARCoNS and fungal colonization that cleave VIP and perpetuate inflammation
- 4–6 weeks for MARCoNS protocols
- 60% MARCoNS eradication with BEG spray (Bactroban, EDTA, Gentamicin)
- Necessary prerequisite for VIP therapy. MARCoNS presence predicts VIP therapy failure. Resistance patterns require culture-directed selection
- Omega-3 fatty acids, statins, immune modulators
- Reduces membrane inflammation, modulates cytokine production, lowers cholesterol-mediated inflammatory pathways
- Ongoing adjunctive therapy
- Variable. Adjunctive role, not monotherapy
- Supportive measures that reduce inflammation burden. Statin use (particularly for lowering C4a) has limited published evidence but clinical practice adoption